Drug Profile
Marimastat
Alternative Names: BB 2516; TA 2516Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Schering-Plough; Tanabe Seiyaku; Vernalis
- Class Antineoplastics; Hydroxamic acids; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Glioma; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 22 Mar 2004 Discontinued - Phase-II for Gastric cancer in Japan (PO)
- 22 Mar 2004 Discontinued - Phase-II for Head and neck cancer in USA (PO)